Amneal Pharmaceuticals (AMRX) Stock Forecast, Price Target & Predictions
AMRX Stock Forecast
Amneal Pharmaceuticals stock forecast is as follows: an average price target of $8.00 (represents a -5.77% downside from AMRX’s last price of $8.49) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
AMRX Price Target
The average price target for Amneal Pharmaceuticals (AMRX) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $4.00. This represents a potential -5.77% downside from AMRX's last price of $8.49.
AMRX Analyst Ratings
According to 2 Wall Street analysts, Amneal Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMRX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amneal Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 02, 2024 | Les Sulewski | Truist Financial | $12.00 | $8.70 | 37.93% | 41.34% |
| Oct 01, 2024 | Les Sulewski | Truist Financial | $10.00 | $8.70 | 14.94% | 17.79% |
| May 03, 2024 | Les Sulewski | Truist Financial | $9.00 | $6.76 | 33.14% | 6.01% |
| Mar 21, 2024 | David Amsellem | Piper Sandler | $8.00 | $6.29 | 27.19% | -5.77% |
| Aug 08, 2022 | - | Goldman Sachs | $4.00 | $3.22 | 24.22% | -52.89% |
The latest Amneal Pharmaceuticals stock forecast, released on Oct 02, 2024 by Les Sulewski from Truist Financial, set a price target of $12.00, which represents a 37.93% increase from the stock price at the time of the forecast ($8.70), and a 41.34% increase from AMRX last price ($8.49).
Amneal Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $11.00 | $9.75 |
| Last Closing Price | $8.49 | $8.49 | $8.49 |
| Upside/Downside | -100.00% | 29.56% | 14.84% |
In the current month, the average price target of Amneal Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amneal Pharmaceuticals's last price of $8.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 08, 2022 | Goldman Sachs | Buy | Buy | Hold |
Amneal Pharmaceuticals's last stock rating was published by Barclays on Aug 13, 2024. The company gave AMRX a "Overweight" rating, the same as its previous rate.
Amneal Pharmaceuticals Financial Forecast
Amneal Pharmaceuticals Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $616.98M | $620.04M | $557.54M | $609.76M | $497.63M | $493.11M | $498.53M | $446.12M | $275.19M | $259.87M |
| Avg Forecast | $693.68M | $657.52M | $619.00M | $630.67M | $602.60M | $589.50M | $561.04M | $535.91M | $438.32M | $411.29M | $573.58M | $334.17M | $185.62M |
| High Forecast | $699.70M | $657.52M | $619.00M | $637.60M | $602.60M | $707.40M | $673.24M | $643.09M | $525.98M | $493.55M | $688.30M | $401.01M | $222.75M |
| Low Forecast | $682.49M | $657.52M | $619.00M | $618.87M | $602.60M | $471.60M | $448.83M | $428.73M | $350.65M | $329.03M | $458.87M | $267.34M | $148.50M |
| # Analysts | 3 | 1 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| Surprise % | - | - | - | 0.98% | 1.03% | 0.95% | 1.09% | 0.93% | 1.13% | 1.21% | 0.78% | 0.82% | 1.40% |
Amneal Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 2 analysts is $619.00M, with a low forecast of $619.00M, and a high forecast of $619.00M. AMRX's average Quarter revenue forecast represents a 0.33% increase compared to the company's last Quarter revenue of $616.98M (Dec 23).
Amneal Pharmaceuticals EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| EBITDA | - | - | - | $14.19M | $135.55M | $98.67M | $135.25M | $82.28M | $96.50M | $104.88M | $35.84M | $87.70M | $57.02M |
| Avg Forecast | $111.83M | $106.00M | $111.46M | $101.67M | $97.14M | $101.32M | $102.14M | $92.11M | $85.78M | $82.63M | $43.80M | $103.18M | $40.73M |
| High Forecast | $112.80M | $106.00M | $133.75M | $102.79M | $97.14M | $121.59M | $122.57M | $110.53M | $102.93M | $99.16M | $52.57M | $123.81M | $48.88M |
| Low Forecast | $110.02M | $106.00M | $89.16M | $99.77M | $97.14M | $81.06M | $81.71M | $73.69M | $68.62M | $66.10M | $35.04M | $82.54M | $32.59M |
| Surprise % | - | - | - | 0.14% | 1.40% | 0.97% | 1.32% | 0.89% | 1.13% | 1.27% | 0.82% | 0.85% | 1.40% |
2 analysts predict AMRX's average Quarter EBITDA for Mar 24 to be $111.46M, with a high of $133.75M and a low of $89.16M. This is 685.29% upper than Amneal Pharmaceuticals's previous annual EBITDA (Dec 23) of $14.19M.
Amneal Pharmaceuticals Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| Net Income | - | - | - | $-98.65M | $9.68M | $-10.09M | $-5.86M | $-6.46M | $6.71M | $115.07M | $-47.88M | $51.53M | $37.45M |
| Avg Forecast | $41.46M | $44.02M | $-2.81M | $22.33M | $40.51M | $-2.55M | $-3.34M | $-2.32M | $5.96M | $90.66M | $-58.52M | $60.63M | $26.75M |
| High Forecast | $47.84M | $44.02M | $-2.25M | $25.52M | $40.51M | $-2.04M | $-2.67M | $-1.86M | $7.15M | $108.79M | $-46.82M | $72.76M | $32.10M |
| Low Forecast | $38.27M | $44.02M | $-3.37M | $22.33M | $40.51M | $-3.06M | $-4.01M | $-2.79M | $4.77M | $72.53M | $-70.23M | $48.50M | $21.40M |
| Surprise % | - | - | - | -4.42% | 0.24% | 3.95% | 1.75% | 2.78% | 1.13% | 1.27% | 0.82% | 0.85% | 1.40% |
Amneal Pharmaceuticals's average Quarter net income forecast for Dec 23 is $22.33M, with a range of $22.33M to $25.52M. AMRX's average Quarter net income forecast represents a 130.60% increase compared to the company's last Quarter net income of $9.68M (Sep 23).
Amneal Pharmaceuticals SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| SG&A | - | - | - | $109.00M | $113.01M | $102.10M | $102.16M | $98.67M | $90.73M | $77.98M | $84.44M | $25.12M | $26.94M |
| Avg Forecast | $121.64M | $115.30M | $128.57M | $110.59M | $105.67M | $116.88M | $93.16M | $106.25M | $80.65M | $61.44M | $103.20M | $29.55M | $19.24M |
| High Forecast | $122.70M | $115.30M | $154.28M | $111.81M | $105.67M | $140.26M | $111.79M | $127.51M | $96.77M | $73.72M | $123.84M | $35.46M | $23.09M |
| Low Forecast | $119.68M | $115.30M | $102.85M | $108.52M | $105.67M | $93.50M | $74.52M | $85.00M | $64.52M | $49.15M | $82.56M | $23.64M | $15.39M |
| Surprise % | - | - | - | 0.99% | 1.07% | 0.87% | 1.10% | 0.93% | 1.13% | 1.27% | 0.82% | 0.85% | 1.40% |
Amneal Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $128.57M, based on 2 Wall Street analysts, with a range of $102.85M to $154.28M. The forecast indicates a 17.95% rise compared to AMRX last annual SG&A of $109.00M (Dec 23).
Amneal Pharmaceuticals EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| EPS | - | - | - | $-0.40 | $0.06 | $-0.07 | $-0.04 | $-0.04 | $0.05 | $0.78 | $-0.37 | $0.45 | $0.33 |
| Avg Forecast | $0.13 | $0.14 | $0.09 | $0.07 | $0.13 | $1.43 | $1.95 | $1.43 | $0.16 | $0.07 | $0.22 | $0.20 | $0.10 |
| High Forecast | $0.15 | $0.14 | $0.09 | $0.08 | $0.13 | $1.43 | $1.95 | $1.43 | $0.19 | $0.09 | $0.26 | $0.24 | $0.12 |
| Low Forecast | $0.12 | $0.14 | $0.09 | $0.07 | $0.13 | $1.43 | $1.95 | $1.43 | $0.13 | $0.06 | $0.18 | $0.16 | $0.08 |
| Surprise % | - | - | - | -5.71% | 0.47% | -0.05% | -0.02% | -0.03% | 0.31% | 11.14% | -1.68% | 2.24% | 3.26% |
According to 4 Wall Street analysts, Amneal Pharmaceuticals's projected average Quarter EPS for Dec 23 is $0.07, with a low estimate of $0.07 and a high estimate of $0.08. This represents a 16.67% increase compared to AMRX previous annual EPS of $0.06 (Sep 23).
Amneal Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.79 | $10.00 | 458.66% | - |
| ASRT | Assertio | $1.03 | $2.88 | 179.61% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.19 | $11.67 | 178.52% | Buy |
| DVAX | Dynavax | $11.78 | $24.50 | 107.98% | Buy |
| EOLS | Evolus | $16.75 | $24.00 | 43.28% | Buy |
| ANIP | ANI Pharmaceuticals | $58.19 | $79.00 | 35.76% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.73 | $66.00 | 30.10% | Buy |
| ALKS | Alkermes | $26.47 | $34.38 | 29.88% | Hold |
| COLL | Collegium Pharmaceutical | $33.46 | $41.50 | 24.03% | Buy |
| NBIX | Neurocrine Biosciences | $122.21 | $147.70 | 20.86% | Buy |
| LFCR | Lifecore Biomedical | $5.88 | $6.50 | 10.54% | Buy |
| ITCI | Intra-Cellular Therapies | $86.54 | $94.50 | 9.20% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| AMRX | Amneal Pharmaceuticals | $8.49 | $8.00 | -5.77% | Buy |
| PAHC | Phibro Animal Health | $23.18 | $18.67 | -19.46% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
AMRX Forecast FAQ
Is Amneal Pharmaceuticals a good buy?
Yes, according to 2 Wall Street analysts, Amneal Pharmaceuticals (AMRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of AMRX's total ratings.
What is AMRX's price target?
Amneal Pharmaceuticals (AMRX) average price target is $8 with a range of $4 to $12, implying a -5.77% from its last price of $8.49. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amneal Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AMRX stock, the company can go down by -5.77% (from the last price of $8.49 to the average price target of $8), up by 41.34% based on the highest stock price target, and down by -52.89% based on the lowest stock price target.
Can Amneal Pharmaceuticals stock reach $13?
AMRX's average twelve months analyst stock price target of $8 does not support the claim that Amneal Pharmaceuticals can reach $13 in the near future.
Did the AMRX's actual financial results beat the analysts' financial forecasts?
Based on Amneal Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $2.39B, beating the average analysts forecast of $1.82B by 31.32%. Apple's EBITDA was $-1.138M, missing the average prediction of $300.13M by -100.38%. The company's net income was $-83.993M, missing the average estimation of $60.28M by -239.34%. Apple's SG&A was $429.68M, beating the average forecast of $333.14M by 28.98%. Lastly, the company's EPS was $-0.48, missing the average prediction of $1.63 by -129.52%. In terms of the last quarterly report (Dec 2023), Amneal Pharmaceuticals's revenue was $616.98M, missing the average analysts' forecast of $630.67M by -2.17%. The company's EBITDA was $14.19M, missing the average prediction of $101.67M by -86.04%. Amneal Pharmaceuticals's net income was $-98.649M, missing the average estimation of $22.33M by -541.84%. The company's SG&A was $109M, missing the average forecast of $110.59M by -1.44%. Lastly, the company's EPS was $-0.4, missing the average prediction of $0.07 by -671.43%